ArticleBMC medicine2021
Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study.
Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 49 citations in OpenAlex.
- SOX1/PAX1 Methylation for Triage of HPV-Positive Women in Cervical Cancer Screening: A Cohort Study.BJOG : an international journal of obstetrics and gynaecology · 2026Article
- HPV testing with 16/18 genotyping for risk stratification among women with normal cytology: a multicenter prospective cohort study from China.Journal of clinical microbiology · 2026Article
- Minimal benefit of co-testing over HPV primary screening with cytology triage from resource-limited settings in China.Communications medicine · 2026Article
- Article
- Factors associated with cervical cancer screening participation in Southwest China: a retrospective database-based cross-sectional study.Frontiers in medicine · 2026Article
- Comparative Oncologic Outcomes in High-Risk Human Papillomavirus-Positive and -Negative Cervical Intraepithelial Neoplasia.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Cervical cancer burden and trends in China, 2000-2020: Asia-Pacific international comparisons and insights for elimination goals.Cancer biology & medicine · 2025Article
- FEN1 plays a key role in the transition from HSIL to CSCC.Scientific reports · 2025Article
- Article
- Triage of women with positive HPV: comparing DNA ploidy analysis with HPV 16/18 genotyping and cervical cytology.Translational cancer research · 2025Article
- Genotypic analysis of human papillomavirus in cervical exfoliated cells from women in Zigong.Virology journal · 2025Article
- Performance of a Full-Coverage Cervical Cancer Screening Program Using on an Artificial Intelligence- and Cloud-Based Diagnostic System: Observational Study of an Ultralarge Population.Journal of medical Internet research · 2024Observational
- Evaluating PAX1 methylation for cervical cancer screening triage in non-16/18 hrHPV-positive women.BMC cancer · 2024Article
- Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination.Nature reviews. Clinical oncology · 2024Review
- Cancer screening programs in South-east Asia and Western Pacific.BMC health services research · 2024Review
- Human Papillomavirus Types and Cervical Cancer Screening among Female Sex Workers in Cameroon.Cancers · 2024Article
- A bibliometric review of predictive modelling for cervical cancer risk.Frontiers in research metrics and analytics · 2024Review
- Cervical intraepithelial neoplasia and cervical cancer in Hunan Province, China, 2020-2023.Frontiers in oncology · 2024Article
- Cervical HPV infection and related diseases among 149,559 women in Fujian: an epidemiological study from 2018 to 2023.Frontiers in microbiology · 2024Article
- Cancer screening in China: a steep road from evidence to implementation.The Lancet. Public health · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRandomized controlled trials have shown a higher sensitivity and longer negative predictive value of high-risk human papillomavirus (HPV) testing than cytology for cervical cancer screening; however, little is known about the effectiveness of HPV testing in middle-income countries. Understanding the characteristics of HPV testing may increase the priority of HPV testing in health policies. The study aims to evaluate the effectiveness of HPV testing in the national cervical cancer screening programme in China.
methodsWe performed a nationwide, population-based study using individual data from the national cervical cancer screening programme in rural China between 2015 and 2017. The analyses included 1,160,981 women aged 35-64 years who underwent cytology alone or high-risk HPV testing with cytology or genotyping triage. The main outcome was cervical intraepithelial neoplasia 2 or worse (CIN2+). We used multivariate logistic regressions and performed sensitivity analyses with propensity score matching to compare the screening positive, colposcopy referral, detection rate, and positive predictive value (PPV).
resultsThe screening positive rates for HPV testing and cytology were 10.1% and 4.0%, respectively. The per protocol colposcopy referral rate of HPV testing was significantly lower than that of cytology (3.5% vs 4.0%), and this difference was mostly due to the low referral threshold of cytology (≥ASC-US). Overall, HPV testing detected more CIN2+ (5.5 vs. 4.4 per 1000, adjusted odds ratio [aOR]=1.18, 95% confidence interval 1.11-1.25) and had a higher PPV (13.8% vs 10.9%, aOR 1.29, 95% CI 1.21-1.37) than cytology. The colposcopy referrals of HPV testing in comparison to cytology differed by income status; it significantly increased in lower-middle-income areas (3.7% vs 3.1%, aOR 1.21, 95% CI 1.17-1.25) and significantly decreased in upper-middle-income areas (3.4% vs 4.9%, aOR 0.69, 95% CI 0.67-0.71). Sensitivity analyses demonstrated the reliability and robustness of the results.
conclusionsThe introduction of HPV testing could improve both the CIN2+ detection rate and efficiency of cervical cancer screening programme, supporting the introduction of primary screening with high-risk HPV testing in China. Further study is needed to investigate the long-term effect of this change.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.